Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

NCT06087653 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Lenalidomide
DRUG: Lenalidomide 25 MG Oral Capsule

Sponsor

Starton Therapeutics, Inc